

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

**(1) RETIREMENT OF NON-EXECUTIVE DIRECTOR;
(2) CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE;
AND
(3) RESIGNATION OF JOINT COMPANY SECRETARY**

Reference is made to the circular of Consun Pharmaceutical Group Limited (the “**Company**”) dated 28 April 2017 (the “**Circular**”) relating to, among others, the re-election of Directors of the Company. Terms used in this announcement shall have the same meaning as those defined in the Circular unless the context requires otherwise.

(1) RETIREMENT OF NON-EXECUTIVE DIRECTOR

The board of Directors of the Company (the “**Board**”) hereby announces that Mr. WANG Shunlong (“**Mr. Wang**”), a non-executive Director, has retired by rotation at the annual general meeting (the “**AGM**”) of the Company held on 31 May 2017 and has not offered himself for re-election as he would like to devote more time to develop his own business. Accordingly, Mr. Wang ceased to be a non-executive Director with effect from the conclusion of the AGM on 31 May 2017. Mr. Wang has confirmed that he has no disagreement with the Board and there is no matter that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and/or the shareholders of the Company.

The Company would like to express its appreciation to Mr. Wang for his contributions to the development of the Company during his tenure of office.

(2) CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE

Following the aforesaid retirement of Mr. Wang, the Board announces the following change of composition of the audit committee of the Company with effect from 31 May 2017:

- (1) Mr. Wang has ceased to be a member of the audit committee of the Company; and
- (2) Mr. SU Yuanfu, an independent non-executive Director of the Company, has been appointed as a member of the audit committee of the Company.

(3) RESIGNATION OF JOINT COMPANY SECRETARY

The Board hereby announces that, with effect from 31 May 2017, Mr. GAO Haien (“**Mr. Gao**”) has resigned as the Company’s joint company secretary due to his commitments to the Group as the board secretary of the Company and the legal representative of the Company’s certain major subsidiaries which require more of his dedication. Mr. Gao confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and/or the shareholders of the Company.

Immediately after the aforesaid resignation, Mr. YAU Chi Ming, the other joint company secretary of the Company who possesses the requisite professional qualification of a listed issuer’s secretary pursuant to Rule 3.28 of the Listing Rules, shall act as the sole company secretary of the Company.

By Order of the Board
Consun Pharmaceutical Group Limited
An Yubao
Chairman

Hong Kong, 31 May 2017

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. LIN Sheng as non-executive Director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.